Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Marie Skłodowska-Curie Action · Running

ORFeus Decoding the dark proteome through interdisciplinary training and research

Coordinator
Prinses Maxima Centrum Voor Kinderoncologie BV, Netherlands
Runs
1 October 2026 to 30 September 2030
Status
Running
EU funding
€4.8m
Total cost
—
Partners
33 organisations in 12 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101309891

What the project is doing

In the project's own words, from its summary on CORDIS.

In the era of precision medicine, we face a startling paradox: while sequencing entire genomes is routine, we remain blind to thousands of small open reading frames (smORFs) encoding microproteins that constitute a vast dark proteome. Recent breakthroughs have revealed their critical roles in diverse biological processes. This previously overlooked layer represents a fundamental gap in our understanding of cellular function and a major untapped source of therapeutic opportunities.

Despite growing recognition by initiatives like Cancer Research UK Grand Challenges, the field remains critically immature with fragmented research, non-standardized methodologies, and most critically, an acute shortage of scientists with multidisciplinary expertise. This human capital bottleneck prevents Europe from establishing leadership. ORFeus addresses this by training 15 interdisciplinary scientists bridging computational biology, proteogenomics, and therapeutic development.

Our consortium unites 15 leading European academics with 14 strategic industry partners spanning technology pioneers, AI innovators, and pharmaceutical developers. Through mandatory integrated training, industry secondments, and cutting-edge technologies, every researcher becomes both computationally and experimentally proficient, a crucial 'bilingual' skillset currently unavailable through traditional programs. The program delivers groundbreaking innovations: AI-powered prediction tools, standardized workflows through the open-access ORFeome platform, and novel cancer immunotherapy targets.

By creating Europe's first comprehensive dark proteome training program, ORFeus transforms this fragmented field into a mature research domain. Our graduates will drive innovation across academia and biotechnology, translate discoveries into clinical applications, and secure Europe's leadership in illuminating this vast unexplored dimension of human biology with profound implications for precision medicine.

Who is involved

OrganisationCityCountryRole
Prinses Maxima Centrum Voor Kinderoncologie BVUtrechtNetherlandsCoordinator
Boehringer Ingelheim Rcv GmbH & Co KgWienAustriaAssociatedpartner
Universiteit GentGentBelgiumParticipant
myNeoGentBelgiumAssociatedpartner
Universite De LausanneLausanneSwitzerlandParticipant
Albert-Ludwigs-Universitaet FreiburgFreiburgGermanyParticipant
Bruker Daltonics GmbH & Co KgBremenGermanyAssociatedpartner
Curevac AGTubingenGermanyAssociatedpartner
European Molecular Biology LaboratoryHeidelbergGermanyAssociatedpartner
Humboldt-Universitaet Zu BerlinBerlinGermanyAssociatedpartner
Max Delbrueck Centrum Fuer Molekulare Medizin in Der Helmholtz-Gemeinschaft (mdc)BerlinGermanyParticipant
Immudex ApsVirumDenmarkAssociatedpartner
Fundacio Institut Hospital Del Mar D Investigacions MediquesBarcelonaSpainParticipant
Universidad Pompeu FabraBarcelonaSpainAssociatedpartner
EIRNA Bio LtdCorkIrelandAssociatedpartner
University College Cork - National University of Ireland, CorkCorkIrelandParticipant
Immagina Biotechnology SRLTrentoItalyAssociatedpartner
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsAssociatedpartner
Koninklijke Nederlandse Akademie Van Wetenschappen - KnawAmsterdamNetherlandsParticipant
Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek ZiekenhuisAmsterdamNetherlandsParticipant
Stichting Oncode InstituteUtrechtNetherlandsAssociatedpartner
Universiteit UtrechtUtrechtNetherlandsAssociatedpartner
Universitetet I OsloOsloNorwayParticipant
Enara Bio LimitedOxfordUnited KingdomAssociatedpartner
Institute of Cancer Research: the Royal Cancer Hospital LbgLondonUnited KingdomParticipant
Oxford Nanopore Technologies LtdOxfordUnited KingdomAssociatedpartner
University of DundeeDundeeUnited KingdomParticipant
University of LeedsLeedsUnited KingdomParticipant
University of LondonLondonUnited KingdomAssociatedpartner
University of SouthamptonSouthamptonUnited KingdomParticipant
Genentech IncSouth San Francisco CaUnited StatesAssociatedpartner
ProFound Therapeutics, Inc.CambridgeUnited StatesAssociatedpartner
Tesorai IncSan DiegoUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI